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Purpose: Based on the assumption that bronchial asthma has not only inflammatory,
but also certain neurogenic paroxysmal mechanism and pathophysiological links with
other non-epileptic paroxysmal inflammatory diseases—migraine and trigeminal
neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in
patients with moderate persistent or severe asthma.
Methods: Sixty-three patients completed randomized double-blind, placebo-con-
trolled trial.
Results: Stable remission was achieved after carbamazepine treatment in 25
patients in active group (n ¼ 33). No significant improvement was registered in
patients of placebo group (n ¼ 30). Following open-label treatment shows high and
stable antiasthmatic efficacy of carbamazepine monotherapy.
Conclusions: Carbamazepine showed high efficacy in therapy of moderate persis-
tent or severe bronchial asthma. Antiasthmatic activity of carbamazepine can be
considered as influence on neurogenic mechanisms of asthma. We suppose that it is
possible to use carbamasepine for therapy of bronchial asthma in clinical practice.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
985433.
.com (M. Lomia),
T. Tchelidze),
ze).Introduction
Bronchial asthma still stays a heavy controlled
disorder: burden of asthma worldwide includes
thousands of lives and billions of US dollars
annually.1 The drug treatment of asthma has
remained essentially unchanged over the past threed.
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agonist and theophylline.2 In spite of definite
achievements, like use of leukotriene antagonists,
pharmacotherapy of asthma remains a serious
problem. Moreover, some drugs for asthma therapy
can be dangerous for patients.3
As we know, bronchial asthma is an inflammatory
disease,1 and neurogenic inflammation may play
important role in asthma mechanisms.4 But we
must remember that asthma is inflammatory dis-
ease with paroxysmal clinical picture.5 We also
know, that migraine and trigeminal neuralgia also
are inflammatory diseases with paroxysmal clinical
picture,6 and neurogenic inflammation plays im-
portant role in mechanisms of these diseases.7,8
Some antiepileptic drugs are very effective in
therapy of migraine9,10 and trigeminal neural-
gia11,12—in more than 80% of cases. But if
antiepileptic drugs are so effective in therapy of
neurogenic inflammatory paroxysmal diseases, is it
possible that some antiepileptic drugs are also
effective in asthma therapy?
Our previous results confirm our hypothesis:
carbamazepine and valproates are highly effective
in asthma monotherapy.13,14 Data of other authors
also are quite remarkable: treatment of children
with epilepsy and concomitant asthma by antiepi-
leptic drugs significantly reduces not only severity of
epilepsy, but also reduces the severity of asthma.15
Due to this we decided to perform double-blind
randomized placebo-controlled trial of antiepilep-
tic drug carbamazepine in patients with moderate
persistent or severe bronchial asthma. The objec-
tive of this study was to assess, in a randomized
double-blind placebo-controlled manner, efficacy
of 3-months-long peroral administration of carba-
mazepine on pulmonary function assessed by PEF,
forced expiratory volume in 1 s (FEV1), severity of
daytime asthma scores and number of night
awakening per week due to asthma symptoms in
patients with moderate-to-severe persistent and
poorly managed bronchial asthma.
We decided to perform trial in relatively small
number of patients, because we anticipated anti-
asthmatic efficacy of antiepileptic agents similar to
high efficacy of anticonvulsants in migraine and
trigeminal neuralgia.Methods
Patients
Aim of study was to evaluate efficacy of carbama-
zepine in treatment of bronchial asthma. Patientsaged 16–65 years old with moderate-to-severe
persistent asthma were recruited for study partici-
pating. Study was performed in Chinese Medical
Centre, Tbilisi, Georgia. Patients were diagnosed
according to the American Thoracic Society defini-
tion of asthma16 and according to GINA recommen-
dations.1 Severity of asthma was classified
according GINA.1
The investigators selected adult patients who
had poorly controlled asthma despite maintenance
therapy with inhaled or oral corticosteroids, beta-
agonists, cromoglycates, antihistamines or theo-
phylline.
Inclusion criteria: out-patients, history of disease
at least for 1 year, poorly controlled asthma due to
various reasons, absence of long-term remissions of
asthma (lasting more than 1 month), and if
pulmonary function testing demonstrated at
least 12% acute response in FEV1 to beta-agonist
inhalation.
Patients were excluded if they had long-lasting
remissions of asthma (more than 1 month) or if
their asthma was strictly seasonal, if they had
concomitant severe diseases, if they suffered from
any serious illness that could make their participa-
tion in the study hazardous or could obscure the
evaluation of the effect of the study drug, if they
had an allergy or intolerance to carbamazepine or
its derivatives, age younger than 16 years old, and
long-term history of smoking. Women who were
breast-feeding, pregnant or not practicing a reli-
able method of birth control were excluded.Study design
The study was a single-centre, double-blind,
randomized, placebo-controlled trial. Before the
blind phase of study, patients were enrolled into a
4-week run-in period during which they completed
daily diary cards, attended laboratory sessions for
pulmonary function testing, and were observed
during office visits for documentation of symptoms.
Patients also were instructed in the administration
of blind capsules (with active drug or placebo) and
of using Mini-Wright peak flow meters. The 74
patients who remained eligible after the run-in
period were randomly assigned to a 13-week (3
months), double-blind phase of treatment with
either 100mg capsules of carbamazepine (N ¼ 37)
or placebo (N ¼ 37). Randomization was computer-
generated in blocks of two treatment regimens:
active drug and placebo. Patients received capsules
equal in size, color, weight and taste, and placed in
standard packets. Allocation sequence and compu-
terized assignation of patients to their groups was
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were enrolled by investigators. Patients agreed to
continue their treatment with corticosteroids, oral
theophyllines, beta-agonists, cromoglycates and
antihistamines.
During the 13-week study period, active drug and
placebo were supplied in identical packets, suffi-
cient for 4 weeks of administration. Patients
returned used packets at each clinic visit and
amount of capsules in these packets were subse-
quently accounted as an independent evaluation of
compliance. Once in 4 weeks patients received the
new packet from allocated packets.
For minimization of adverse reactions dosage of
carbamazepine and placebo were increased gradu-
ally: first 5 days patients received 1 capsule one
time per day, next 5 days—1 capsule twice per day,
next 5 days—2 capsule twice per day, and then—2
capsules three times per day till to end of study.
This practice is very usual for administration of
antiepileptic drugs. In case of appearing transitory
adverse reactions during dose growth patients were
allowed to return to previous smaller dose for 5
days and then begin dose titration in the same
mode.
Morning and evening PEF were registered by
patients (Mini-Wright peak flow-meters, Wright-
McKerrow scale) before the study, every day
throughout the study and after the study. FEV1
and additionally PEF were registered by portable
spirometer ‘‘Spirodoc’’ (MIR, Italy) before the
study, every week during morning clinical visits
and after the study.
FEV1 before and after use of 400 mg (4 puffs)
inhaled salbutamol—was registered in the morning
before and after the study.
Routine blood and urine analysis was evaluated in
each patient before the study, once a month during
clinical visits and after the study.
Every day throughout the study in their diary cards
patients recorded the severity of daytime asthma,
using a 0–3 scale with 0 indicating no symptoms and 3
indicating severe symptoms, nighttime awakenings
due to asthma symptoms, adverse events, their
morning and evening peak-flow data and usage of
their routine antiasthmatic drugs except carbama-
zepine. At each clinic visit during the trial diary-
symptom cards were collected, maximum expiratory
flow-volume curves were obtained and patients were
interviewed as to incidence and severity of daytime
and nocturnal symptoms.
In special circumstances, when patients could
not visit the site due to various reasons, we planned
missed clinical visit to nearest possible day or
investigator physicians visited to patients’ home if
it was requested by patient.Patients were allowed to abandon any other
previously prescribed routine antiasthmatic treat-
ment under our physicians’ careful supervision in
case of asthma symptoms disappearance, lasted at
least 1 month after beginning the trial. The reason
of this was our previous clinical experience: after
receiving of high positive effect of antiepileptic
drugs in asthma our out-patients usually discon-
tinued any other antiasthmatic treatment too
abruptly. Due to economical reasons (no effective
medical insurance) patients tried to avoid buying
non-effective drugs for concomitant use with
antiepileptic drug. We strongly advised to reduce
long-term peroral or parenteral hormonal therapy
gradually, and we gave to patients oral and written
instructions concerning danger of systemic adverse
effects in case of sudden abandoning of high-dose
peroral or parenteral hormonal therapy.
Our study was compliant with Helsinki Declara-
tion and GCP principles, and study was approved by
local Ethics Committee and subjects gave their
written consent to participate.
Endpoint definition: Efficacy of carbamazepine
was evaluated by disappearance of any asthmatic
syndrome, and normalization of PEF, FEV1 (primary
outcomes), daytime scores of asthma, number of
nighttime awakening per week due to asthma
symptoms and also by discontinuation of any other
antiasthmatic therapy except carbamazepine
(secondary outcomes).
Safety of the treatment: the safety of the
treatment was evaluated at each visit when
patients were questioned for any adverse events
and health problems that may have occurred. All
unusual signs and symptoms were recorded for
further consideration. Routine blood and urine
analyses were performed every month throughout
the study.
Adverse events: patients recorded any adverse
events on the diary cards and were additionally
questioned in a general manner at each visit
regarding possible adverse events. Any adverse
events reported were graded as mild, moderate, or
severe and assessed for any relationship to the
study medication.
Stopping rules of the study were multiple resis-
tant adverse effects of the therapy, abnormalities in
laboratory analyses and significant deterioration of
asthma symptoms. Patients were allowed to stop
participating in out trial in any time.Statistical analysis
The null hypothesis for patients enrolled in trial
was that carbamazepine was no better than
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added to an existing treatment regimen. Wilcoxon
signed rank test was used throughout for statistical
analysis of non-parametric related data. Man-
n–Whithey U-test was used for analysis of non-
parametric independent data. A P-valuep0.05 was
considered significant. For statistical analysis of
data we used SPSS for Windows (release 11.0). Data
are presented as mean7standard deviation.Results
Patients population
Recruitment was performed from October 4, 2004,
to December 24, 2004, and trial lasted till to March
31, 2005. Seventy-four patients were enrolled into
the blind phase of the study. Eleven patients were
excluded from investigation at the beginning of the
trial (4 from carbamazepine group: 3 due to stable
side effects—dizziness and somnolence, 1—due to
non-compliance, and 7 from placebo group due to
non-compliance). Thus, in total 63 patients (33 of
carbamazepine group and 30 of placebo group)
completed the trial and were analyzed (see
Table 1).
Peak expiratory flow
Analysis of symptoms showed, that asthmatic
attacks disappeared after 6–16 days of treatmentTable 1 Baseline characteristics of 63 study patients.
Groups/variables Carbamazepine group
(n ¼ 33)
Age (years) 50.3710.8
Gender
Male 13 (39.4%)
Female 20 (60.6%)
Duration of asthma
(years)
12.279.4
Severity of asthma
Moderate persistent 7 (21.2%)
Severe 26 (78.8%)
PEF (L/min) 234767
FEV1 (L) 1.1370.44
Concomitant medication 33 (100%)
1. Theophylline 25 (75.8%)
2. Beta-agonists 22 (66.7%)
3. Steroids 17 (51.5%)
4. Cromoglycates 10 (30.3%)
5. Antihistamines 7 (21.2%)in 25 patients of carbamazepine group, and also we
observed quite gradual increase in peak-flow rates
during first month of study.
After 1 month of the treatment in 25 patients of
carbamazepine group we have registered signifi-
cant increase of peak-flow rates, which gradually
persisted during next weeks and almost reached
calculated normal level at the end of 3rd month. In
other 8 patients of carbamazepine group peak-
flow rates remained at the pre-treatment level (see
Fig. 1, and Table 2).
We did not observe any significant changes of
peak-flow rates in 30 patients of placebo group.
Forced expiratory volume in 1 s (FEV1)
FEV1 also increased gradually after the beginning of
the trial (see Fig. 2). After 4 weeks of treatment
FEV1 in patients of carbamazepine group was
significantly higher compared to FEV1 in patients
of placebo group. Increase of FEV1 in carbamaze-
pine group has continued till the end of the study.
In placebo group FEV1 stayed at pre-treated level
(see Fig. 2 and Table 2).
FEV1 before and after inhaled beta-agonist
Mean increase of morning FEV1 after the use of
400 mg (4 puffs) inhaled salbutamol more than by
12% was registered in the morning before the study
in patients of active and placebo groups. After the
study only patients of placebo group had the meanPlacebo group (n ¼ 30) Significance of
difference
45.5715.8 NS (P40:05)
12 (40%) NS (P40:05)
18 (60%) NS (P40:05)
16.4710.7 NS (P40:05)
8 (26.7%) NS (P40:05)
22 (73.3%) NS (P40:05)
242784 NS (P40:05)
1.2070.55 NS (P40:05)
30 (100%) NS (P40:05)
21 (70%) NS (P40:05)
16 (53.3%) NS (P40:05)
21 (70%) NS (P40:05)
10 (33.3%) NS (P40:05)
11( 36.7%) NS (P40:05)
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Figure 1 Morning peak-flow rates.
Table 2 Patient characteristics before and after the treatment: carbamazepine and placebo group.
Groups/variables Carbamazepine group Placebo group
Before the trial After the trial Before the trial After the trial
# of patients 33 (100%) 33 (100%) 30 (100%) 30 (100%)
# of patients with everyday
attacks
23 (69.7%) 4 (12.1%)** 21 (70%) 22 (73.3%)
# of patients without asthma
attacks
0 25 (75.8%)** 0 0
PEF (L/min) 234767 3887118** 242784 242784
% predicted PEF 50.9713.5 82.3716.8** 51.4712.5 51.4712.0
FEV1 (L) 1.1370.44 2.2370.85** 1.2070.55 1.2370.58
% predicted FEV1 39.5713.4 76.2720.9** 39.8712.9 40.9714.0
FEV1 increase in % from
baseline after salbutamol
inhalation
16.673.4 8.574.7** 17.574.3 13.375.1
Daytime scores of asthma
(0–3 scale)
1.7371.10 0.3070.85** 1.6771.21 1.6371.13
Number of nights per week
with awakening due to
asthma
5.3972.50 1.0972.34** 5.1372.26 5.0772.43
Concomitant medication: 33 (100%) 7 (21.2%)** 30 (100%) 30 (100%)
1. Theophylline 25 (75.8%) 5 (15.2%)** 21 (70%) 21 (70%)
2. Beta-agonists 22 (66.7%) 7 (21.2%)** 16 (53.3%) 16 (53.3%)
3. Steroids 17 (51.5%) 5 (15.2%)** 21 (70%) 19 (63.7%)
4. Cromoglycates 10 (30.3%) 1 (3.0%)** 10 (33.3%) 11 (36.7%)
5. Antihistamines 7 (21.2%) 3 (9.1)** 11( 36.7%) 11 (36.7%)
*Difference between this group and placebo is statistically significant (Pp0:05).
**Difference between this group and placebo is statistically significant (Pp0:01).
M. Lomia et al.1992increase of morning FEV1 after inhaled salbutamol
more than by 12%. In patients from carbamazepine
group mean increase of morning FEV1 after inhaledsalbutamol was only till 8.574.7% vs. FEV1 initial
level, and this is significantly less in comparison to
placebo group (see Table 2).
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Asthma as neurogenic disease: A trial with carbamazepine 1993Patients without asthmatic attacks
In 25 patients from 33 (75.8% of carbamazepine
group, see Supplementary Table) asthmatic attacks
disappeared after 7–15 days of treatment by
carbamazepine. Other 8 patients from carbamaze-
pine group and 30 patients from placebo group
had asthma attacks till the end of the study (see
Table 2). So, we observed appearance and sig-
nificant growth of the number of patients without
asthmatic attacks: at the end of the treatment 25
patients out of 33 patients from carbamazepine
group had no asthmatic attacks at all.
Daytime scores of asthma and number of
night awakening per week due to asthma
symptoms
Daytime scores of asthma and night awakening
rating due to nocturnal asthma symptoms were
decreased significantly after first 4 weeks of study
in patients from carbamazepine group, and then
stayed on this level till the end of the study. No
significant decrease of these parameters occurred
in patients from placebo group (see Figs. 3 and 4,
Table 2).
Concomitant treatment with routine
antiasthmatic drugs
Twenty-five patients, where treatment by carba-
mazepine was effective, after 2–4 weeks of study
treatment discontinued any previously prescribed
treatment (see Table 2). No one from these
patients received high doses of peroral hormonesduring years, and due to this they were allowed to
abandon their antiasthmatic therapy except carba-
mazepine in case of excellent efficacy of investiga-
tional drug, as they were instructed in run-in period
before the clinical phase of study.Adverse events
In 74 patients enrolled into the study 3 patients of
active group (1 man and 2 women) were excluded
from the study due to stable moderate adverse
events—dizziness and somnolence. In 7 patients (2
men and 5 women) we observed transient and mild
adverse events only in first 2 weeks after the
beginning of the study, and they did not excluded
from the study. In active group dizziness had 2
women and 1 man, headache—1 man and 2 woman.
In placebo group somnolence had 1 woman.Following open-label treatment
After randomized double-blind phase of the study
patients continue treatment in open-label mode.
According to our data, 6 months after the start of
our treatment by carbamazepine all 25 responders
of carbamazepine group continued treatment by
this drug after the study. Peak-flow rates in all
these patients remained in the normal range after
finishing the blind phase of trial. All 25 responders
did not take any antiasthmatic treatment except
carbamazepine and they did not have any signs of
asthma.
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M. Lomia et al.1994Discussion
In this study it become possible to prove that in
more than 75.8% of patients from carbamazepine
group asthma attacks were avoided by the use of
carbamazepine. In carbamazepine group in com-
pare to placebo group the daytime scores of asthma
and number of nights with awakening per week due
to asthma decreases significantly, in 25 patients
asthmatic attacks disappeared completely, PEF and
FEV1 increases significantly, stable remission was
achieved after treatment during months, concomi-
tant antiasthmatic therapy is reduced and even
discontinued.Such results confirm the results of our previous
trials.13,14,17 Some previous experimental findings
also confirm our results: it was shown that
carbamazepine suppresses bronchoconstriction in
guinea pigs, induced by some neuromediators and
biologically active agents, including substance P.18
Other confirmation of our results is that the
treatment of children with epilepsy and concomi-
tant asthma by antiepileptic drugs also significantly
reduces the severity of asthma.15
It seems quite possible that bronchial asthma is
mainly paroxysmal neurogenic inflammatory disor-
der and airways inflammation in asthma is not only
immune, but also neurogenic process. Role of
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of bronchial tone,1 but no one tried to sup-
press inflammation and paroxysmal nature of
bronchoconstriction in asthma by antiepileptic
drugs, like in therapy of neurogenic paroxysmal
inflammatory disorders migraine11,12 and trigeminal
neuralgia.7,10
It is also possible that carbamazepine and some
other anticonvulsants have antiasthmatic activity
due their direct peripheral influence on airways
wall. But combination of strong antimigrenous and
antiasthmatic activity of antiepileptic drugs does
not confirm this assumption. It is known that almost
all other drugs with peripheral activity in migraine
can provoke asthma attacks and vice versa: so, non-
steroidal anti-inflammatory drugs are effective for
the treatment of migraine,19 but at the same time
they are contraindicated in bronchial asthma20;
beta-adrenergic agonists are effective for bronchial
asthma,1 but beta-adrenoblockers—for migraine,21
and at the same time beta-adrenoblockers are
contraindicated in bronchial asthma.20 If we sup-
pose peripheral influence of antiepileptic drugs on
bronchial tone, we must make assumption about
existence of some new types of peripheral recep-
tors in airways wall. We also could not find some
evidences about peripheral therapeutic activity of
carbamazepine in medical literature.
It is interesting that carbamazepine shows
efficacy also in some other neurogenic inflamma-
tory disorders. Some authors described patients
with psoriasis which had dramatic improvement of
their condition after administration of carbamaze-
pine.22,23 Similar to asthma neurogenic inflamma-
tion plays important role in mechanism of
psoriasis,24,25 and substance P plays important role
in inducing of this inflammation.26,27
Due to high efficacy of carbamazepine in patients
with moderate persistent and severe asthma we
suppose that it is possible to use carbamasepine for
therapy of bronchial asthma in clinical practice.Acknowledgements
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